Terms: = Prostate cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA
652 results:
1. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
[TBL] [Abstract] [Full Text] [Related]
2. Homologous Recombination Repair Deficiency in Metastatic prostate cancer: New Therapeutic Opportunities.
Piombino C; Pipitone S; Tonni E; Mastrodomenico L; Oltrecolli M; Tchawa C; Matranga R; Roccabruna S; D'Agostino E; Pirola M; Bacchelli F; Baldessari C; Baschieri MC; Dominici M; Sabbatini R; Vitale MG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731844
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Correlates of prostate-Specific Membrane Antigen Expression and Response to
Raychaudhuri R; Mo G; Tuchayi AM; Graham L; Gulati R; Pritchard CC; Haffner MC; Yezefski T; Hawley JE; Cheng HH; Yu EY; Grivas P; Montgomery RB; Nelson PS; Chen DL; Hope T; Iravani A; Schweizer MT
JCO Precis Oncol; 2024 Apr; 8():e2300634. PubMed ID: 38662984
[TBL] [Abstract] [Full Text] [Related]
4. LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Kulkarni A; Zhou J; Biyani N; Kathad U; Banerjee PP; Srivastava S; Prucsi Z; Solarczyk K; Bhatia K; Ewesuedo RB; Sharma P
Cancer Res Commun; 2024 May; 4(5):1199-1210. PubMed ID: 38630886
[TBL] [Abstract] [Full Text] [Related]
5. Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells.
Wu Y; Liu P; Chen W; Bai S; Chen S; Chen J; Xu X; Xia J; Wu Y; Lai J; Sun C; Lao Z; Wan X; Wu Z
Int J Hyperthermia; 2024; 41(1):2335201. PubMed ID: 38583875
[TBL] [Abstract] [Full Text] [Related]
6. The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate and colorectal cancer in the UK.
Lally P; Kennedy F; Smith S; Beeken RJ; Buck C; Thomas C; Counsell N; Wyld L; Martin C; Williams S; Roberts A; Greenfield DM; Gath J; Potts HWW; Latimer N; Smith L; Fisher A
Cancer Med; 2024 Mar; 13(6):e7124. PubMed ID: 38529687
[TBL] [Abstract] [Full Text] [Related]
7. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
8. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
9. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive prostate cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract] [Full Text] [Related]
10. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
11. LCP1-mediated cytoskeleton alterations involve in arsenite-triggered malignant phenotype of human immortalized prostate stromal cells.
Yang Y; Zhou M; Huang Y; Ye X; Mo Y; Huang Y; Wang S
Food Chem Toxicol; 2024 Apr; 186():114548. PubMed ID: 38417537
[TBL] [Abstract] [Full Text] [Related]
12. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract] [Full Text] [Related]
13. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract] [Full Text] [Related]
14. Germline DNA Damage Response Gene Mutations in Localized prostate cancer.
Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
[No Abstract] [Full Text] [Related]
15. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
16. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
17. Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.
Kal S; Mahata S; Jati S; Mahata SK
Peptides; 2024 Feb; 172():171147. PubMed ID: 38160808
[TBL] [Abstract] [Full Text] [Related]
18. Leukocyte Telomere Length and the Risk of prostate cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study.
Lv K; Wu Y; Yang G; Hao X; Huang S; Song T; Yuan Q
J Gerontol A Biol Sci Med Sci; 2024 Mar; 79(3):. PubMed ID: 38085929
[TBL] [Abstract] [Full Text] [Related]
19. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With prostate cancer.
Brown LC; Zhu J; Mauer E; Thiede SN; Macera L; Stein MM; Taxter T; Raghavan D; Burgess EF
JCO Precis Oncol; 2023 Sep; 7():e2300378. PubMed ID: 38061006
[TBL] [Abstract] [Full Text] [Related]
20. Polygenic Risk Score Modifies prostate cancer Risk of Pathogenic Variants in Men of African Ancestry.
Hughley RW; Matejcic M; Song Z; Sheng X; Wan P; Xia L; Hart SN; Hu C; Yadav S; Lubmawa A; Kiddu V; Asiimwe F; Amanya C; Mutema G; Job K; Ssebakumba MK; Ingles SA; Hamilton AS; Couch FJ; Watya S; Conti DV; Darst BF; Haiman CA
Cancer Res Commun; 2023 Dec; 3(12):2544-2550. PubMed ID: 38014910
[TBL] [Abstract] [Full Text] [Related]
[Next]
